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Background: The use of quantitative real-time PCR (qPCR) has allowed for precise quantification of parasites in the
prepatent period and greatly improved the reproducibility and statistical power of controlled human malaria
infection (CHMI) trials. Parasitological data presented here are from non-immunized, control-challenged subjects
who participated in two CHMI trials conducted at the Walter Reed Army Institute of Research (WRAIR).
Methods: Standardized sporozoite challenge was achieved through the bite of five Anopheles stephensi mosquitoes
infected with the 3D7clone of the NF54 strain of Plasmodium falciparum. Blood smears were scored positive when
two unambiguous parasites were found. Analysis of parasitological PCR data was performed on log-transformed
data using an independent sample t-test when comparing the two studies. The multiplication rate of blood-stage
parasites was estimated using the linear model.
Results: On average, parasites were detected 4.91 days (95% CI = 4.190 to 5.627) before smears. The earliest
parasites were detected within 120 hours (5.01 days) after challenge. Parasite densities showed consistent cyclic
patterns of blood-stage parasite growth in all volunteers. The parasite multiplication rates for both studies was 8.18
(95% CI = 6.162 to 10.20). Data showed that at low parasite densities, a combination of sequestration and stochastic
effects of low copy number DNA may impact qPCR detection and the parasite detection limit.
Conclusion: Smear positive is an endpoint which antimalarial rescue is imperative whereas early detection of
parasitological data by qPCR can allow for better anticipation of the endpoint. This would allow for early treatment
to reduce clinical illness and risk for study participants. To use qPCR as the primary endpoint in CHMI trials, an
algorithm of two positives by qPCR where one of the positives must have parasite density of at least 2 parasites/μL
is proposed.Background
Controlled human malaria infection (CHMI) is increas-
ingly being used to assess the efficacy of malaria vaccines
as well as to evaluate antimalarial drug candidates [1,2].
Data obtained from CHMI are critical in the decision-
making process of whether or not to proceed with more
costly Phase IIb field trials [1]. CHMI trials allow for de-
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[1,2], which can be informative for further optimization
of a vaccine or drug candidate. Studies have shown a
high correlation between natural and experimental infec-
tions, which further validates the importance of using
CHMI in testing new vaccines or drugs [1].
In CHMI trials, subjects are inoculated (challenged) with
either Plasmodium falciparum or Plasmodium vivax spo-
rozoites from bites of infectious, laboratory-reared, female
anopheline mosquitoes. After being challenged, subjects
are closely monitored for signs and symptoms of malariaLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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stage parasites is performed by the examination of blood
smears at regular intervals starting five to seven days post
challenge [3]. Subjects are treated with antimalarial drugs
when patent parasitaemia is confirmed by blood smears
following criterion set forth in the study protocol. The
detection threshold of parasites on Giemsa-stained
thick films is about two to 20 parasites/μL depending
on the expertise of the microscopist and the number of
high-powered fields examined on a thick blood film.
The comparative prepatent period of treated subjects
and control subjects is used to assess efficacy of the
vaccine or drug being tested [3].
The development of quantitative real-time PCR (qPCR)
and other molecular techniques, which are more sensitive
than microscopy has allowed for precise quantification of
parasites during the prepatent period [4-6]. The qPCR
data can be used to estimate liver parasite load (for pre-
erythrocytic vaccines) or blood-stage multiplication rate
(for erythrocytic vaccines), providing additional detailed
information on the efficacy of the vaccine or drug can-
didate [7-10]. The mean prepatent period for control
subjects challenged with sporozoites by mosquito bite
is ~11 days (ranges seven to 20 days), with almost 100%
of subjects bitten by five infectious mosquitoes deve-
loping patent parasitaemia [11-13]. Once the parasite
emerges from the liver, the number in peripheral blood
depends on multiplication rates and sequestration of
parasites. Previous studies have detected parasites by
PCR as early as 5.5 days after sporozoite challenge [6],
with parasites detected by qPCR on average two to four
days before detection by blood smears [3,6].
The use of molecular analysis has enhanced the reprodu-
cibility and statistical power of CHMI [1]. Harmonization
of CHMI study methodology will further strengthen the
use of molecular analysis and will allow more accurate
comparison of studies conducted in different centres [3].
Further, a recent study showed that small CHMI trials
even with small number of subjects are sufficiently
powered to detect protective biological effects induced
by pre-erythrocytic and/or blood-stage candidate vac-
cines if parasitaemia is measured daily by qPCR [14].
This study set-out to perform descriptive analysis of
parasitological dataset from two CHMI trials recently
conducted at the Walter Reed Army Institute of
Research (WRAIR) in Silver Spring, MD, USA. The data




Samples used for analysis in this study were from infec-
tivity control challenge subjects enrolled in two different
studies conducted at WRAIR in 2012. All the subjectsdeveloped infection following challenge. These subjects
did not receive any investigational product or licensed
antimalarial medication prior to challenge by the bite of
infectious mosquitoes. Participants were malaria-naïve
adult males and females from 18–50 years of age. Protocols
for both studies were approved by the WRAIR Institutional
Review Board and by the Human Subjects Research
and Review Board of the Surgeon General of the US
Army at Fort Detrick, Maryland. Participants in both
studies provided written, informed consent before
screening and enrolment and had to pass an assessment
of understanding.
Infection procedures
Standardized sporozoite challenge was achieved through
the bite of five Anopheles stephensi mosquitoes infected
with the 3D7clone of the NF54 strain of P. falciparum.
In both studies, 3D7 was prepared from the same master
seed. Parasitaemia was detected by the routine daily
examination of blood smears from day 5 to day 18 follo-
wing challenge. Blood smears were analysed every two
days from day 20 until day 28 post-challenge for any indi-
vidual who had not yet become parasitaemic. Food and
Drug Administration (FDA) approved oral antimalarials
licensed in the USA were administered under directly
observed therapy to treat uncomplicated malaria as
soon as parasitaemia was detected by microscopy.
Sample collection and processing
Samples were routinely collected every morning for blood
smears and qPCR. In addition, samples were collected if a
subject became symptomatic outside of scheduled, routine
collection times. However, samples collected outside the
routine times were not analysed in this study. Samples
were collected in EDTA blood tubes and aliquoted for im-
mediate use, or immediately stored in −20°C. For micro-
scopic analysis, thick smears were prepared by spreading
10 μL of blood on a slide. The 10 μL of blood was smeared
to make a 1 cm × 2 cm rectangle, with two such rectangles
per slide. To read the smear, five passes across the 1-cm
dimension of the smear were made for asymptomatic indi-
viduals and 21 passes were made for symptomatic individ-
uals, unless the individual was found to be positive before
the completion of the examination. The volume of blood
examined by making five passes was 0.55 μL. Slides were
examined by two independent readers under oil immer-
sion at 1000× magnification. Blood smears were scored
positive when two unambiguous parasites were found.
The same team of microscopists was responsible for
smear analysis in both studies.
Real-time PCR assay
The qPCR analysis was done in real-time using reagents,
procedures and methods as previously described [15,16].
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have been described previously [17]. Samples were ana-
lysed using the genus-specific PLU assay and endogenous
control RNaseP assay, which was performed as a multiplex
assay. The WHO International Standard for P. falciparum
DNA (obtained from National Institute for Biological
Standards and Control; NIBSC, Hertfordshire, UK.
Referred to herein as NIBSC standard), plasmid DNA or
combination of both was used as standard for quantifica-
tion of the parasite density in all the qPCR assays per-
formed. Details of the reagents and analysis methods have
been described previously [15,16]. Briefly, DNA was puri-
fied from 200 μL whole blood and eluted in 200 μL elution
buffer or water using EZ1 automated purification system
(Qiagen, Valencia, CA, USA) with the EZ1 DNA blood kit
(Qiagen) following the manufacturer’s recommendation.
For qPCR assay, 1 μL DNA was added in 4 μL master
mix. Each assay was run on a 96-well plate with NIBSC
standard. The performance of the NIBSC standard and
RNaseP for individual assays was assessed to determine
the success of the analysis. The amplification plot for each
assay was individually assessed to ensure true amplifica-
tion of the assay when Cq (quantification cycle, can also
be referred to as the threshold cycle [Ct]) values were
obtained. The qPCR assays were performed within four
hours of blood collection.
Data analysis
Statistical analyses were performed using Graph-Pad
Prism (San Diego, CA, USA) and STATA software version
10 (College Station, TX, USA). Prepatent period was
defined as length of time between challenge and detection
of a positive blood smear. Analysis of parasitological PCR
data was performed on log-transformed data using an in-
dependent sample t-test when comparing the two studies.
The multiplication rate of blood-stage parasites was esti-
mated using the linear model as recently described [18].
The cycles of parasite growth were estimated as follows:
the first cycle started the first day parasites were detected
until day 8, the second cycle was day 9–10, the third
cycle was day 11–12, and the fourth cycle was day 13–14
where applicable.Table 1 Time to parasitaemia (days), showing the number of
Mean Std Dev Max
First study (n = 11)
Smear 11.34 0.93 13.02
qPCR 7.01 0.07 7.12
Second study (n = 5)
Smear 12.54 1.33 14.00
qPCR 6.38 0.89 7.01Results
Time to parasitaemia
Data from 16 unvaccinated infectivity control subjects
enrolled in two different malaria vaccine trials at the
WRAIR were analysed by qPCR. Table 1 shows the
mean number of days before detection of parasites in
both studies by blood smears and qPCR. The earliest
parasites detected were in a subject from the second
study where parasites were detected by qPCR 120 hours
(5.01 days) after the time of challenge, with a parasite
density of 0.174 parasite/μL. Parasites were detected by
qPCR in all study subjects within seven days following
challenge. In the first study, parasites were detected on
average 4.34 days (95% CI = 3.70 to 4.98) before smears,
whereas in the second study, parasites were detected on
average 6.17 (95% CI = 4.57 to 7.77) days before smears.
Figure 1A and B are survival curves showing the per
cent of subjects negative by both smears and qPCR for
first and second study.Parasite density
Parasite densities showed consistent cyclic patterns of
blood-stage parasite growth in all volunteers from both
studies. Figure 2 shows the geometric mean of parasite
density from both studies. Parasites in the second study
were detected sooner by qPCR compared to the first
study and at a lower density. Parasite geometric mean
density first cycle was 0.444 parasites/μL (95% CI = 0.274
to 0.718) for the first study and 0.202 parasites/μL (95%
CI = 0.107 to 0.383) for the second study. Geometric
mean parasite density by smears for the first study was
3.29 parasites/μL (95% CI 2.00 to 5.42) and 1.68 (95%
CI = 0.97 to 2.92) for the second study. Geometric mean
parasite density by qPCR analysis on the first day of
qPCR positivity for the first study was 0.394 parasites/μL
(95% CI = 0.272 to 0.572) and 0.174 parasites/μL (95%
CI = 0.079 to 0.383) for second study. Interestingly, the
geometric mean parasite density by qPCR at the day of
smear positive for first study was 23.92 parasites/μL
(95% CI = 16.43 to 34.80) and 35.74 parasites/μL (95%
CI = 25.43 to 50.23) for second study.subjects from the first and second study
Min Median 25% 75% P Value
10.11 10.96 10.91 11.97 0.0001
6.91 6.98 6.95 7.07
10.96 11.98 11.43 13.94 0.0004
5.01 6.93 5.47 7.00
Figure 1 Time to smear and qPCR positive. Survival curves showing the percent of subjects negative by both smears and qPCR. (A) first study
and (B) second study.
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Figure 3 shows parasite multiplication rate (PMR) for
the first and second study. The mean PMR for first and
second studies were 8.26 (range = 3.5-13.37) and 8.00
(range = 3.98-13.77), respectively. However, parasites in
the second study, which were detected sooner and at
a lower parasite density, remained low until day 11
(Figure 2). The geometric mean parasite density on day
11 was 22.57 parasites/μL (CI = 15.37-33.15) for the first
study compared to 2.02 parasites/μL (CI = 0.37-11.03) for
second study. This is reflected by the fact that on day 10
and 11, eight out of 11 (seven on day 11) subjects were
found parasite positive by smear for the first study
whereas for the second study, subjects did not become
smear positive until day 12 (two subjects), day 13 (one
subject) and day 14 (two subjects). Table 2 shows the geo-
metric mean parasite density in parasites/μL in the first,
second, third, and fourth cycles for first and second study.
Figure 4A and B show the geometric mean parasite den-
sity in parasites/mL per multiplication cycle for individual
subjects. Data clearly indicate that growth rates for theFigure 2 Parasite density as measured by qPCR. The geometric mean i
day which qPCR was initiated (day 5 after challenge) until the day the subjsecond study were initially slow in the first and second or
third cycle but increased rapidly in the third or fourth
cycle.
Effect of parasite sequestration in qPCR detection
The numbers of parasites in peripheral blood depend on
multiplication rates and sequestration. At low parasite
density, stochastic or random sampling effects of low
copy number of DNA during PCR amplification leads to
fluctuation of results between replicate analyses. A com-
bination of sequestration and stochastic effects may im-
pact qPCR detection and the Cq values obtained at low
densities. Table 3 shows Cq values from two subjects for
whom qPCR analysis was repeated in eight replicates for
two consecutive days. The initial qPCR runs were done
in triplicate (shown in bold). The qPCR assay for Subject
ID 01 performed on 02FEB, demonstrates stochastic
effects due to low parasite density. When the qPCR
assay was initially run in triplicate on 02FEB, only one
Cq value out of the three replicates was detected at cycle
42.08, which is outside the set assay limit of Cq value ofs shown from both studies with 95% confidence intervals, from the
ects became smear positive and treatment was initiated.
Figure 3 Parasite multiplication rate for trials. Individual data are
plotted, lines represent mean.
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cation. However, when repeated in eight replicates, five
Cq values were recorded with standard deviation (SD) of
0.983. As the parasite multiplied and density increased
(24 hours), all Cq values were within the detectable
range (with lower SD) the following day. When initially
run in triplicate, subject ID 02 had one Cq value out of
the three replicates detected on 02FEB at cycle 34.47 but
none was detected on 03FEB. However, when repeated
in eight replicates, five Cq values were recorded on 02FEB
and four Cq values were recorded on 03FEB. These data
clearly demonstrate that a negative Cq value can be due to
a lack of parasites in the sample, low parasite density
because it is early in the parasite life cycle, low numbers of
parasites due to sequestration, or the stochastic effects of
low copy number DNA template, which demonstrates the
limits of qPCR (molecular) assays.
Discussion
This study show detailed estimations of critical parameters
in the parasite life cycle from CHMI studies conducted
at WRAIR using qPCR measurements of parasitaemia
in infectivity control (non-vaccinated), malaria-naive
(non-immune) volunteers. Parasite analysis was done in
real time and results were available within four to six
hours from the time of blood collection. Parasites were
detected in all volunteers who eventually developed
malaria within seven days of the challenge, with the
earliest detection being at 5.01 days. Previous studies
have demonstrated parasites are detected by qPCR on
average of two to four days before microscopy [3,6]. Inter-
estingly, parasites were detected on average 6.17 daysTable 2 Parasite cycles (parasite/μL)
1st cycle (95% CI) 2nd cycle (95%
First study 0.44 (0.27 to 0.72) 2.41 (1.33 to 4.3
Second study 0.20 (0.11 to 0.38) 0.29 (0.14 to 0.6before microscopy in the second study. In one of the sub-
jects, parasites were detected 7.93 days before detection by
microscopy. This is the largest interval that has been
reported in CHMI between qPCR positivity and blood
smear parasite detection. In the first study, parasites were
detected on average 4.34 days before microscopy. In both
studies, there were no false qPCR positives based on data
obtained from infectivity controls and vaccine recipients
(data to be reported elsewhere).
In CHMI studies, the primary endpoint of blood-stage
infection is the first detection of parasites by micros-
copy. Since CHMI studies mostly recruit malaria-naïve,
healthy volunteers, there has been increasing discussion
about whether qPCR should replace microscopy as the
primary endpoint for clinical diagnosis in order to re-
duce malaria symptomatology, clinical illness and risk
for study participants. Use of qPCR for endpoint diagno-
sis with the first appearance of PCR positive sample may
be suitable for pre-erythrocytic (liver stage) vaccines.
However, it would be less useful in the evaluation of
vaccines and drugs with blood-stage activity as efficacy
for these can only be obtained by evaluating blood-stage
parasite growth over a sufficient period of time [14].
Treatment based on qPCR would decrease the time
window required for detailed analysis and estimation of
critical parameters in the parasite life cycle required for
measuring the efficacy of blood-stage vaccines [3]. De-
velopment of a qPCR treatment algorithm is therefore
critical in keeping the time window long enough to
evaluate vaccine efficacy yet short enough to treat volun-
teers in time (before they would be smear positive) to
reduce clinical illness. In this study, the geometric mean
parasite density by qPCR on the day of first positive
blood smear was 23.92 parasites/μL (95% CI = 16.43-
34.80) and 35.74 parasites/μL (95% CI = 25.43-50.23) for
the first and second study, respectively. The geometric
mean parasite density by qPCR on the day prior to the
first positive smear was 5.78 parasites/μL (95% CI =
2.92-11.43) and 6.12 parasites/μL (95% CI = 1.87-20.00)
for first and second study, respectively. In a study by
Roestenberg et al. which compared parasitological data
from CHMI studies, the lowest geometric mean peak
parasitaemia detected was 7.08 parasites/μL [10]. In
another study, using pooled data, the geometric mean
parasitaemia and second and third cycles were deter-
mined to be 4.49 and 11.37 parasites/μL, respectively
[14]. Most molecular assays used in CHMI studies have
a threshold of about 0.02 parasites/μL [4,6,17,19]. ToCI) 3rd cycle (95% CI) 4th cycle (95% CI)
7) 24.55 (16.87 to 35.73) Nil
4) 3.71 (0.41 to 33.86) 14.15 (3.36 to 59.66)
Table 3 Effect of parasite sequestration in qPCR detection
ID Date Cq Cq Mean Cq SD ID Date Cq Cq Mean Cq SD
01 02FEB 42.08 42.08 01 03FEB 30.58 31.02 0.49
Und 42.08 31.54 31.02 0.49
Und 42.08 30.92 31.02 0.49
Und 33.76 0.98 31.05 30.86 0.32
32.97 33.76 0.98 30.51 30.86 0.32
34.92 33.76 0.98 31.24 30.86 0.32
Und 33.76 0.98 30.95 30.86 0.32
34.74 33.76 0.98 30.30 30.86 0.32
33.00 33.76 0.98 31.18 30.86 0.32
33.13 33.76 0.98 30.82 30.86 0.32
Und 33.76 0.98 30.82 30.86 0.32
ID Date Cq Cq Mean Cq SD ID Date Cq Cq Mean Cq SD
02 02FEB 34.47 34.47 02 03FEB Und
Und 34.47 Und
Und 34.47 Und
37.30 36.22 2.01 33.93 34.34 0.68
Und 36.22 2.01 34.99 34.34 0.68
33.28 36.22 2.01 Und 34.34 0.68
37.30 36.22 2.01 Und 34.34 0.68
35.05 36.22 2.01 Und 34.34 0.68
Und 36.22 2.01 34.84 34.34 0.68
Und 36.22 2.01 33.60 34.34 0.68
38.17 36.22 2.01 Und 34.34 0.68
Bold Cq values indicate the initial qPCR runs which were done in triplicate.
Figure 4 Geometric mean parasite density per multiplication cycle for individual volunteers. Panel A shows data from the first study and
panel B shows data from the second study.
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rithm of two positives, not necessarily on consecutive
days (because of parasite sequestration), where one of
the positives must have parasite density of at minimum
two parasites/μL is proposed. This is a parasite density
that is well within range as detected by qPCR at the day
of positive smears in this and other studies. This will
allow enough time window for analysis of the effect of
the vaccine while still allowing initiation of antimalarial
treatment one to two days before becoming smear posi-
tive. For this algorithm to be effective however, it is im-
portant that CHMI centres use harmonized qPCR analysis
and common reference standard DNA for determination
of parasite density. In addition, as more data are collected
from more centres, the recommendations regarding mini-
mum parasite density should be adjusted.
Inter-individual variation is probably the most impor-
tant factor in determining the sensitivity of sporozoite
challenge trials, which might be influenced by the para-
site inoculum size, parasite fitness, and human (innate)
immune factors [14]. Use of malaria-naïve volunteers in
CHMI studies helps reduce variance due to immune fac-
tors. However, parasite inoculum size and parasite fitness
is still an issue in sporozoite challenge trials. The variabi-
lity in prepatent period, parasite growth rates and densities
found between first and second study could be due to the
infectivity of the sporozoites, the number of sporozoites
per mosquito, or the number of sporozoites inoculated by
the bites of five infected mosquitoes. This has been shown
to vary from centre to centre, between trials at the same
centre, and even between individuals in the same trial at
the same centre [20]. Although it has been suggested that
the use of vialed sporozoites administered by needle and
syringe for challenge could reduce these variations [3,20],
it is important to be cautious since this is not a natural
route of sporozoite infection and will undoubtedly have
immune response implications [1]. In addition, it will not
address the issues of variation in parasite fitness and
innate host variability.Conclusion
This study demonstrates reproducibility of CHMI stu-
dies conducted at the WRAIR and the use of qPCR for
measurements of parasitaemia. An algorithm that can
be used for qPCR as an endpoint diagnosis has been
proposed. Use of qPCR as an endpoint diagnosis is
likely to appeal to FDA and other authorities because it
will reduce malaria symptomatology, clinical illness and
risk for study participants. However, all the benefits of
using qPCR as an endpoint diagnosis must be weighed
against the legacy of using smears as the endpoint and
the backward compatibility with data collected from
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